Biosimilars: what US regulators might learn from others
This article was originally published in SRA
Executive Summary
As the US Food and Drug Administration works to implement an approval pathway for biosimilars, Erika Lietzan and Emily Alexander look at how the agency's counterparts around the world have dealt with some of the key issues in this complex area.